NLS Pharmaceutics AG is a biotechnology business based in the US. NLS Pharmaceutics shares (NLSP) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in NLS Pharmaceutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NLSP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
NLS Pharmaceutics stock price (NASDAQ: NLSP)Use our graph to track the performance of NLSP stocks over time.
NLS Pharmaceutics shares at a glance
|Latest market close||$3.45|
|52-week range||$2.06 - $4.70|
|50-day moving average||$3.12|
|200-day moving average||$3.33|
|Wall St. target price||$10.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy NLS Pharmaceutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy NLS Pharmaceutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
NLS Pharmaceutics price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||10.22%|
|3 months (2021-04-30)||-5.74%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
NLS Pharmaceutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-150.64%|
|Return on equity TTM||0%|
|Market capitalisation||$33.1 million|
TTM: trailing 12 months
Shorting NLS Pharmaceutics shares
There are currently 51,834 NLS Pharmaceutics shares held short by investors – that's known as NLS Pharmaceutics's "short interest". This figure is 37.8% up from 37,610 last month.
There are a few different ways that this level of interest in shorting NLS Pharmaceutics shares can be evaluated.
NLS Pharmaceutics's "short interest ratio" (SIR)
NLS Pharmaceutics's "short interest ratio" (SIR) is the quantity of NLS Pharmaceutics shares currently shorted divided by the average quantity of NLS Pharmaceutics shares traded daily (recently around 647925). NLS Pharmaceutics's SIR currently stands at 0.08. In other words for every 100,000 NLS Pharmaceutics shares traded daily on the market, roughly 80 shares are currently held short.
To gain some more context, you can compare NLS Pharmaceutics's short interest ratio against those of similar companies.
However NLS Pharmaceutics's short interest can also be evaluated against the total number of NLS Pharmaceutics shares, or, against the total number of tradable NLS Pharmaceutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NLS Pharmaceutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NLS Pharmaceutics shares in existence, roughly 0 shares are currently held short) or 0.0086% of the tradable shares (for every 100,000 tradable NLS Pharmaceutics shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NLS Pharmaceutics.
Find out more about how you can short NLS Pharmaceutics stock.
NLS Pharmaceutics share dividends
We're not expecting NLS Pharmaceutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Novartis (NVS.US) (3.72% forward annual dividend yield)
NLS Pharmaceutics overview
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland. .
Stocks similar to NLS Pharmaceutics
NLS Pharmaceutics in the news
New Strong Sell Stocks for July 30th
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
Frequently asked questionsWhat percentage of NLS Pharmaceutics is owned by institutions?
Currently 0.629% of NLS Pharmaceutics shares are held by institutions. When does the fiscal year end for NLS Pharmaceutics?
NLS Pharmaceutics's fiscal year ends in December. Where is NLS Pharmaceutics based?
NLS Pharmaceutics's address is: Alter Postplatz 2, Stans, Switzerland, 6370
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert